Clinical Trials List
2025-06-02 - 2029-12-31
Phase III
Recruiting9
ICD-10I25.10
Atherosclerotic heart disease of native coronary artery without angina pectoris
ICD-9429.2
Cardiovascular disease, unspecified
A single-arm, multicenter, open-label extension (OLE) trial was conducted to evaluate the long-term safety and tolerability of pelacarsen (TQJ230) in participants completing the main trial of Lp(a)HORIZON.
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
Novartis Taiwan Co., Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/27
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 蔣俊彥 無
- Zhih-Cherng Chen 無
- 洪俊聲 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王兆弘 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 薛書凱 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
• Treatment-induced adverse events (TEAEs)
• Serious treatment-induced adverse events (TESAEs)
• Treatment discontinuation due to TEAE/TESAE
• TEAEs of particular concern
Observations or changes/variations from the baseline period for the following items:
• Laboratory safety assessments
• Vital signs
Inclution Criteria
2. Participants who are still receiving the designated investigational drug at their end-of-study (EOS) follow-up visit after completing the main trial.
Exclusion Criteria
2. Participants with a history or evidence of clinically significant abnormalities, symptoms, or diseases that, as determined by the trial administrator or a Novartis physician (if consulted), would put the participant at risk or interfere with trial participation, including but not limited to the situations mentioned in Tables 6-3 and 6-5 of the program.
3. Participants who were receiving other investigational drugs or devices prior to the open-label treatment phase.
4. Women who are pregnant or breastfeeding.
5. Women of childbearing age, unless they are using highly effective contraception.
The Estimated Number of Participants
-
Taiwan
68 participants
-
Global
5700 participants
